TRENDING TOPICS
3286 articles found for "investing"
China Vanke, once the country's largest homebuilder, narrowly avoided a $284 million default last week. The close call exposes the ongoing fragility of China's property sector.
Oil services giant SLB has surged 14% to start 2026 as investors recognize energy companies' role in powering AI data centers. Here's why the rally may continue.
Spot Bitcoin ETFs have shed $1.1 billion in three trading days, nearly erasing 2026 gains as the Crypto Fear and Greed Index slides toward the fear zone.
Treasury Secretary Scott Bessent urges the Federal Reserve to continue cutting interest rates, calling lower borrowing costs the key to unleashing stronger growth.
Goldman Sachs predicts the US economy will grow 2.6% in 2026, outpacing consensus by 0.6 percentage points. Tax cuts, Fed rate reductions, and reduced tariff drag are driving optimism.
BlackRock's Jay Jacobs argues that retail investor access to Bitcoin through ETFs is just beginning. With $287 million in single-day inflows, the crypto giant sees 2026 as pivotal.
Tesla delivered 1.63 million vehicles in 2025, marking an 8.5% annual decline. With EV sales stalling, the company's robotaxi and Optimus bets become increasingly critical.
Moderna stock surges 19% in the first week of 2026 after filing for regulatory approval of its mRNA-based flu vaccine. Here's what investors need to know about the company's pivot.
Meta signed landmark nuclear agreements with Vistra, Oklo, and TerraPower to supply 6.6 GW of power for AI data centers. The deals make Meta one of the largest corporate nuclear buyers in history.
Intel stock surged 10% after CEO Lip-Bu Tan met with President Trump at the White House. The U.S. government's $8.9 billion stake has doubled in value as the 'national champion' semiconductor strategy gains momentum.
Apple has staged a remarkable recovery in China, with iPhone 17 driving a 37% surge in monthly sales. One in four smartphones sold in China is now an iPhone.
The 44th Annual JPMorgan Healthcare Conference kicks off as J&J announces a $14.6 billion acquisition of Intra-Cellular Therapies. The deal signals a new era of pharma M&A.